Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Clinical Trials

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Imlunestrant
Drug: Omeprazole
Drug: Repaglinide
Drug: Quinidine
Drug: Rosuvastatin
Drug: Dextromethorphan
Drug: Digoxin

First Posted Date: 2022-07-06

Last Posted Date: 2022-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 113

Registration Number: NCT05444556

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AZD5462
Drug: Midazolam
Drug: Rosuvastatin
Drug: Digoxin

First Posted Date: 2022-05-27

Last Posted Date: 2023-12-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 32

Registration Number: NCT05395117

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-92480
Drug: Itraconazole
Drug: Digoxin
Drug: Rifampin
Drug: Rosuvastatin

First Posted Date: 2022-05-25

Last Posted Date: 2023-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT05389722

Locations: 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: AB-106, digoxin

First Posted Date: 2022-05-03

Last Posted Date: 2024-11-21

Lead Sponsor: Nuvation Bio Inc.

Target Recruit Count: 16

Registration Number: NCT05357911

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China

A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: HRS5091 Tablets
Drug: Midazolam Maleate Tablets
Drug: Warfarin Sodium Tablets
Drug: Omeprazole Enteric Capsules
Drug: Vitamin K1 Tablets
Drug: Digoxin Tablets
Drug: Rosuvastatin Calcium Tablets

First Posted Date: 2022-03-10

Last Posted Date: 2022-12-23

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 22

Registration Number: NCT05273775

Locations: 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Effect of Testosterone Treatment on Drug Metabolism and Transport

Active, not recruiting

Conditions: Transgender Persons

First Posted Date: 2021-11-11

Last Posted Date: 2024-03-18

Lead Sponsor: University of Washington

Target Recruit Count: 12

Registration Number: NCT05116293

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Evobrutinib
Drug: Digoxin
Drug: Sumatriptan
Drug: Metformin
Drug: Rosuvastatin

First Posted Date: 2021-10-01

Last Posted Date: 2022-01-11

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 40

Registration Number: NCT05064488

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Warfarin sodium tablets
Drug: Digoxin tablet
Drug: Probenecid tablets
Drug: DBPR108 tablets

First Posted Date: 2021-09-16

Last Posted Date: 2022-03-10

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05045313

Locations: 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, China

Digoxin In Treatment of Alcohol Associated Hepatitis

Phase 2

Recruiting

Conditions: Alcohol-Induced Disorders
Steatohepatitis Caused by Ingestible Alcohol
Acute Alcoholic Hepatitis
Chemical and Drug Induced Liver Injury